Halozyme Therapeutics Inc (HALO) saw a price increase of 3.30%, reaching a 20-day high, amid positive market conditions with the Nasdaq-100 up 0.88% and the S&P 500 up 0.63%.
This surge is attributed to the collaboration agreement between Halozyme and Skye Bioscience, allowing Skye to license Halozyme's ENHANZE® drug delivery technology for developing a subcutaneous formulation of nimacimab. This partnership is expected to enhance treatment potential in the obesity market and includes plans for a Phase 2b clinical trial to assess the drug's efficacy.
The collaboration not only strengthens Halozyme's competitive position in the biopharmaceutical sector but also promises sustainable revenue growth through mid-single digit royalties from Skye's sales, reinforcing investor confidence in the company's future.
Wall Street analysts forecast HALO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HALO is 78.00 USD with a low forecast of 56.00 USD and a high forecast of 92.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast HALO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HALO is 78.00 USD with a low forecast of 56.00 USD and a high forecast of 92.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
2 Hold
1 Sell
Moderate Buy
Current: 73.340
Low
56.00
Averages
78.00
High
92.00
Current: 73.340
Low
56.00
Averages
78.00
High
92.00
Morgan Stanley
Overweight
downgrade
$79 -> $75
2026-01-08
Reason
Morgan Stanley
Price Target
$79 -> $75
AI Analysis
2026-01-08
downgrade
Overweight
Reason
Morgan Stanley lowered the firm's price target on Halozyme to $75 from $79 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech's outperformance in 2026 as commercial names transition from "capital consumers to producers" and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.
TD Cowen
Buy
upgrade
$79 -> $90
2026-01-08
Reason
TD Cowen
Price Target
$79 -> $90
2026-01-08
upgrade
Buy
Reason
TD Cowen raised the firm's price target on Halozyme to $90 from $79 and keeps a Buy rating on the shares. The firm adjusted price targets in the diagnostic tools group group as part of a Q4 preview. Investor sentiment continues to inflect upward with 2026 guidance updates "key for positioning within the sector recovery," the analyst tells investors in a research note. TD is most positive on stocks "with clear multi-year frameworks and multiple avenues for upside to derisked growth assumptions."
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for HALO
Unlock Now
Goldman Sachs
Neutral -> Sell
downgrade
$56
2025-12-04
Reason
Goldman Sachs
Price Target
$56
2025-12-04
downgrade
Neutral -> Sell
Reason
Goldman Sachs downgraded Halozyme to Sell from Neutral with a $56 price target. A central debate for Halozyme is the long-term value of its Enhanze royalty model, which faces a substantial post-2030 revenue cliff as roughly 70% of royalties roll off contract between 2030-2035 and appears unlikely to be offset through typical business-development pacing, the analyst tells investors in a research note. Current valuation implies a terminal value that assumes roughly $34B in new partner product revenue by 2041, a level that seems achievable only under optimistic scenarios despite the recent Elektrofi acquisition, the firm says.
Goldman Sachs
Neutral
maintain
$54 -> $56
2025-11-18
Reason
Goldman Sachs
Price Target
$54 -> $56
2025-11-18
maintain
Neutral
Reason
Goldman Sachs raised the firm's price target on Halozyme to $56 from $54 and keeps a Neutral rating on the shares. Halozyme announced a global non-exclusive collaboration and license agreement with Merus to use Halozyme's Enhanze technology in the development of a subcutaneous formulation of petosemtamab, the analyst tells investors in a research note. While strategically positive, Goldman doesn't expect the announcement to meaningfully move the stock.
About HALO
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED. It also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
